Effect of Sacubitril/Valsartan on Reduced Right Ventricular Ejection Fraction in Patients With CTD
Status:
Not yet recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
Heart failure, one of the leading causes of connective tissue disease (CTD) mortality, has
attracted increasing attention. Currently, no known study had focused on the effect of
sacubitril/valsartan on right ventricular dysfunction and in the systemic disease induced
heart disease. We aimed to observe the effect of sacubitril/valsartan on primary endpoints (6
minutes walking test and myocardial fibrosis) in CTD patients with right ventricular ejection
fraction reduction (RV-HFrEF).